NEW ORLEANS — Recent years have brought several significant advances in dry eye disease treatment, Amy Lin, MD, said during Cornea Subspecialty Day at the American Academy of Ophthalmology meeting.
New treatments for dry eye disease (DED) include novel mechanisms of action and delivery systems.
“This translates to more options for our patients,” Lin said.
Lin discussed FDA-approved DED treatments including Eysuvis (loteprednol etabonate ophthalmic suspension 0.25%, Kala Pharmaceuticals), Tyrvaya (varenicline solution 0.03 mg, Oyster Point Pharma) and iTEAR100 (Olympic